News

The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28

Abbott Laboratories stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and traditional market multiples currently point to the shares trading at a discount. The share price is down about 30.7% over the past year, which has pushed investor sentiment lower while opening a potential valuation gap. Progress in colorectal cancer diagnostics and partnerships in continuous glucose monitoring can support long term cash...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ consensus estimates.

Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.

Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results and increased its full-year earnings guidance, sending its shares about 2. 5% higher in premarket trading.

Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AMD, Dell, Intel, and Micron shares fall as Wall Street questions how long the AI spending boom can last.

Stock Market Today: Tech futures tumbled Thursday as Sandisk and SK Hynix plunged. TSMC sold off on earnings.

Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.

Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.

US equity markets were mostly tracking in the red before the opening bell Thursday as traders await

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, discusses the future of the field.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.

ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.

Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring.

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

Abbott Laboratories (NYSE:ABT) is one of the Best Monopoly Stocks to Buy According to Hedge Funds. On June 30, Baird initiated coverage on the company’s stock with an “Outperform” rating, setting a price objective of $121.00. The firm sees Abbott Laboratories (NYSE:ABT)’s portfolio as delivering steady top-line and earnings growth over the upcoming several years. As per […]

In July 2026, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration strengthens Tandem’s ecosystem by pairing its advanced AutoBolus-enabled AID algorithm with one of Europe’s most widely used CGM platforms, potentially broadening...

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technology now connects with Abbott’s FreeStyle Libre 3 Plus CGM across five European countries. See our latest analysis for Tandem Diabetes Care. The Abbott tie up comes as Tandem Diabetes Care’s 1 year total shareholder return is down 1.15%, while the share price has fallen 28.49% year to date to $15.41. This suggests recent momentum has faded despite the product expansion...

Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.

The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.